SAREPTA THERAPEUTICS

41.00

21-May-25 13:15:13

15 minutes delayed

Stocks

+1.01

+2.53%

Today's range

40.80 - 44.14

ISIN

N/A

Source

NASDAQ

NetDania - New 12 months Low: SAREPTA THERAPEUTICS INC. - COMMON STOCK

11 Mar 2025 10:19:10 By NetDania Notify
NetDania - New 12 months Low: SAREPTA THERAPEUTICS INC. - COMMON STOCK

10 Mar 2025 10:33:53 By NetDania Notify
NetDania - New 12 months Low: SAREPTA THERAPEUTICS INC. - COMMON STOCK

04 Mar 2025 09:46:51 By NetDania Notify
NetDania - New 12 months Low: SAREPTA THERAPEUTICS INC. - COMMON STOCK

03 Mar 2025 15:38:11 By NetDania Notify
NetDania - New 12 months Low: SAREPTA THERAPEUTICS INC. - COMMON STOCK

27 Feb 2025 09:45:10 By NetDania Notify
NetDania - New 12 months Low: SAREPTA THERAPEUTICS INC. - COMMON STOCK

18 Feb 2025 09:47:18 By NetDania Notify
NetDania - New 12 months High: SAREPTA THERAPEUTICS INC. - COMMON STOCK

21 Jun 2024 09:45:14 By NetDania Notify
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

31 Jan 2023 18:20:00 By Nasdaq GlobeNewswire
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2022 Net Product Revenues

09 Jan 2023 13:28:00 By Nasdaq GlobeNewswire
Sarepta Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 08:30:00 By Nasdaq GlobeNewswire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30 Dec 2022 17:58:49 By Nasdaq GlobeNewswire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30 Nov 2022 18:00:00 By Nasdaq GlobeNewswire
Sarepta Therapeutics Announces That U.S. FDA has Accepted for Filing and Granted Priority Review for the Biologics License Application for SRP-9001, Sarepta’s Gene Therapy for the Treatment of Ambulant Individuals with Duchenne Muscular Dystrophy

28 Nov 2022 07:00:00 By Nasdaq GlobeNewswire
Sarepta Therapeutics to Present at the Evercore ISI HealthCONx Conference

23 Nov 2022 08:30:00 By Nasdaq GlobeNewswire
Sarepta Therapeutics Announces Third Quarter 2022 Financial Results and Recent Corporate Developments

02 Nov 2022 16:05:01 By Nasdaq GlobeNewswire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

31 Oct 2022 18:00:31 By Nasdaq GlobeNewswire
Sarepta Therapeutics to Announce Third Quarter 2022 Financial Results

26 Oct 2022 08:30:00 By Nasdaq GlobeNewswire
Sarepta Therapeutics Presents New Data from its Gene Therapy and RNA Platforms at World Muscle Society 2022

07 Oct 2022 08:30:00 By Nasdaq GlobeNewswire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30 Sep 2022 18:15:00 By Nasdaq GlobeNewswire
Sarepta Therapeutics Submits Biologics License Application for SRP-9001 for the Treatment of Ambulant Patients with Duchenne Muscular Dystrophy

29 Sep 2022 08:30:00 By Nasdaq GlobeNewswire

<<
<
1
2
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.